Literature DB >> 7947993

Distribution of immunoreactive malondialdehyde-modified low-density lipoprotein in human serum.

K Kotani1, M Maekawa, T Kanno, A Kondo, N Toda, M Manabe.   

Abstract

We developed a sensitive enzyme-linked immunosorbent assay (ELISA) for detection of malondialdehyde-modified low-density lipoprotein (MDA-LDL) in human serum. A monoclonal antibody against MDA-LDL (ML25) used in our method recognized not only MDA-LDL but also other MDA-modified proteins. However, MDA-LDL was able to be detected specifically by using a combination of ML25 and an antibody specific for apolipoprotein B (apo B) (AB16), which was conjugated with beta-galactosidase. Using this method, measurable amounts of MDA-LDL were detected in the sera of 40 healthy individuals. MDA-LDL was observed to be mainly distributed in the human LDL fraction separated by density gradient ultracentrifugation, while in each lipoprotein subfraction the largest amount of MDA-LDL per protein was found at a subfraction between LDL and HDL. The particle size of LDL in this fraction was smaller than that of LDL in the main LDL fraction, as assessed by electrophoresis. In addition, LDL oxidized by Cu2+ was also detectable with this method. We conclude that our method is sensitive and specific for MDA-LDL and might be useful for investigating MDA-LDL in the human circulation.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7947993     DOI: 10.1016/0005-2760(94)90100-7

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  24 in total

1.  Circulating malondialdehyde modified LDL is a biochemical risk marker for coronary artery disease.

Authors:  T Amaki; T Suzuki; F Nakamura; D Hayashi; Y Imai; H Morita; K Fukino; T Nojiri; S Kitano; N Hibi; T Yamazaki; R Nagai
Journal:  Heart       Date:  2004-10       Impact factor: 5.994

2.  Immunological evidence for hypochlorite-modified proteins in human kidney.

Authors:  E Malle; C Woenckhaus; G Waeg; H Esterbauer; E F Gröne; H J Gröne
Journal:  Am J Pathol       Date:  1997-02       Impact factor: 4.307

Review 3.  Mechanisms and consequences of carbamoylation.

Authors:  Sigurd Delanghe; Joris R Delanghe; Reinhart Speeckaert; Wim Van Biesen; Marijn M Speeckaert
Journal:  Nat Rev Nephrol       Date:  2017-07-31       Impact factor: 28.314

4.  Characterization of the effect of serum bilirubin concentrations on coronary endothelial function via measurement of high-sensitivity C-reactive protein and high-density lipoprotein cholesterol.

Authors:  Satoshi Yoshino; Shuichi Hamasaki; Sanemasa Ishida; Tetsuro Kataoka; Akiko Yoshikawa; Naoya Oketani; Keishi Saihara; Hitoshi Ichiki; So Kuwahata; Shoji Fujita; Takuro Takumi; Issei Yoshimoto; Mitsuhiro Nakazaki; Chuwa Tei
Journal:  Heart Vessels       Date:  2012-03-29       Impact factor: 2.037

5.  Impact of malondialdehyde-modified low-density lipoprotein on coronary plaque vulnerability in patients not receiving lipid-lowering therapy: a whole coronary analysis with multislice-computed tomography.

Authors:  Tsuyoshi Ito; Taku Ichihashi; Hiroshi Fujita; Tomonori Sugiura; Nobuyuki Ohte
Journal:  Heart Vessels       Date:  2017-10-24       Impact factor: 2.037

6.  Development of capture assays for different modifications of human low-density lipoprotein.

Authors:  Gabriel Virella; M Brooks Derrick; Virginia Pate; Charlyne Chassereau; Suzanne R Thorpe; Maria F Lopes-Virella
Journal:  Clin Diagn Lab Immunol       Date:  2005-01

7.  Circulating oxidized LDL, increased in patients with acute myocardial infarction, is accompanied by heavily modified HDL.

Authors:  Naoko Sawada; Takashi Obama; Shinji Koba; Takashi Takaki; Sanju Iwamoto; Toshihiro Aiuchi; Rina Kato; Masaki Kikuchi; Yuji Hamazaki; Hiroyuki Itabe
Journal:  J Lipid Res       Date:  2020-04-14       Impact factor: 5.922

Review 8.  Oxidative modification of LDL: its pathological role in atherosclerosis.

Authors:  Hiroyuki Itabe
Journal:  Clin Rev Allergy Immunol       Date:  2009-08       Impact factor: 8.667

9.  Effects of fluvastatin on plasma levels of low-density lipoprotein subfractions, oxidized low-density lipoprotein, and soluble adhesion molecules: a twenty-four-week, open-label, dose-increasing study.

Authors:  Yasuhiko Homma; Koichiro Homma; Shinichi Iizuka; Kamon Iigaya
Journal:  Curr Ther Res Clin Exp       Date:  2003-04

10.  Effects of PCSK9 Inhibitor on Favorable Limb Outcomes in Patients with Chronic Limb-Threatening Ischemia.

Authors:  Yusuke Sato; Hiroyasu Uzui; Tetsuji Morishita; Yoshitomo Fukuoka; Kanae Hasegawa; Hiroyuki Ikeda; Naoto Tama; Kentaro Ishida; Shinsuke Miyazaki; Hiroshi Tada
Journal:  J Atheroscler Thromb       Date:  2020-09-25       Impact factor: 4.928

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.